IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Public ClinicalTrials.gov record NCT04086264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Study identification
- NCT ID
- NCT04086264
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 218 participants
Conditions and interventions
Conditions
Interventions
- Azacitidine Drug
- IMGN632 Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2019
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2027
- Last update posted
- Aug 13, 2025
2019 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center /ID# 269273 | Duarte | California | 91010 | — |
| University Of California Irvine Medical Center /ID# 269275 | Orange | California | 92868 | — |
| Moffitt Cancer Center /ID# 269269 | Tampa | Florida | 33612 | — |
| Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 269642 | Chicago | Illinois | 60611-3015 | — |
| Dana-Farber Cancer Institute /ID# 269267 | Boston | Massachusetts | 02215 | — |
| University of Michigan /ID# 269079 | Ann Arbor | Michigan | 48109-2800 | — |
| Mayo Clinic Hospital Rochester /ID# 269643 | Rochester | Minnesota | 55905 | — |
| Roswell Park Cancer Institute /ID# 269266 | Buffalo | New York | 14263 | — |
| New York Presbyterian Hospital Weill Cornell Medical Center /ID# 269271 | New York | New York | 10461 | — |
| Duke University Health System /ID# 269268 | Durham | North Carolina | 27705-3976 | — |
| Cleveland Clinic - Cleveland /ID# 269272 | Cleveland | Ohio | 44195 | — |
| MD Anderson Houston /ID# 269265 | Houston | Texas | 77030-4000 | — |
| Fred Hutchinson Cancer Research Center /ID# 269270 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04086264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04086264 live on ClinicalTrials.gov.